Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines

Oladejo, Mariam; Paulishak, Wyatt; Wood, Laurence M.

doi:10.1016/j.semcancer.2022.12.003

Cited by 24 publications

(10 citation statements)

References 223 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, immune checkpoint inhibitors and cancer vaccines have limitations in immunotherapy [ 15 ]. Successful anti-tumour response to cancer vaccines depends on the recognition of specific tumour antigens.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Current status and future of cancer vaccines: A bibliographic study

Yu,

Zhao,

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…They can prevent excessive activation of the immune system and achieve self-tolerance [ 29 ]. At this stage, the combination of ICIs with cancer vaccines can induce an anti-tumour immune response more efficiently and overcome the immunosuppressive tumour microenvironment [ 15 ]. Tumor microenvironment: …”

Section: Discussionmentioning

confidence: 99%

Current status and future of cancer vaccines: A bibliographic study

Yu,

Zhao,

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Consequently, CTLA4 effectively dampens T-cell activation. Additionally, CTLA4 can reduce the surface expression of CD80 and CD86 on APCs via trans-endocytosis, thereby curtailing cytotoxic T-cell activation 95 . The TME of various cancers has been shown to accumulate CD4 + CD25 + Foxp3 + regulatory T cells (Tregs), which also express elevated levels of CTLA4 96 .…”

Section: Tumor Immunotherapy Development and Historical Findings On T...mentioning

confidence: 99%

Influence of Microbiota on Tumor Immunotherapy

Yu,

Li,

et al. 2024

Int. J. Biol. Sci.

View full text Add to dashboard Cite

The role of the microbiome in immunotherapy has recently garnered substantial attention, with molecular studies and clinical trials providing emerging evidence on the pivotal influence of the microbiota in enhancing therapeutic outcomes via immune response modulation. However, the impact of microbial communities can considerably vary across individuals and different immunotherapeutic approaches, posing prominent challenges in harnessing their potential. In this comprehensive review, we outline the current research applications in tumor immunotherapy and delve into the possible mechanisms through which immune function is influenced by microbial communities in various body sites, encompassing those in the gut, extraintestinal barrier, and intratumoral environment. Furthermore, we discuss the effects of diverse microbiome-based strategies, including probiotics, prebiotics, fecal microbiota transplantation, and the targeted modulation of specific microbial taxa, and antibiotic treatments on cancer immunotherapy. All these strategies potentially have a profound impact on immunotherapy and pave the way for personalized therapeutic approaches and predictive biomarkers.

show abstract

“…Immune checkpoint inhibitors (ICIs) are applied to treat kinds of malignant tumors, including breast cancer [12,13]. However, the response of patients with different tumors to immune checkpoint inhibitors shows extensive therapeutic differences, with only some patients showing signi cant bene ts [14,15]. Based on the clinical practice, the immune checkpoint proteins (ICPs) include PD-1, PD-L1, and CTLA-4 [16].…”

Section: Introductionmentioning

confidence: 99%

Low expression of TOX predicts poor prognosis of patients with breast cancer in the real world: a retrospective study

Tan,

Wu,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: TOX is a transcription factor that is implicated in the regulation of T cell exhaustion in tumors. TOX has been proven to have prognostic value in some malignant tumors. We aim to analyze the expression of TOX in breast cancer patients, and the association between TOX and prognostic significance in patients with breast cancer. Methods: 313 breast cancer patients were enrolled into the current study. The expression of TOX was determined by the immunohistochemistry assay in breast cancer tissues. The relationships between TOX and clinical pathological variables in breast cancer were performed via chi-square test. Survival curves were performed by Kaplan-Meier method and log-rank test. The potential independent factors were assessed by Cox model regression analyses. Nomogram models, calibration curve, decision curve analyses were applied to analyze the clinical utility of the predictive models. Results: According the semi-quantitative scoring under electron microscope, 129 breast cancer patient samples were classified into low group, and 184 breast cancer patient samples were classified into high group. Patients with high expression of TOX had survived longer than those with low expression of TOX (DFS: 71.70 vs. 64.05 months; OS: 81.03 vs. 73.72 months), and the difference in survival time between the two groups was statistically significant (DFS: χ2=11.6300, P=0.00065; OS: χ2=11.4200, P=0.00073). Patients with high expression of TOX had survived longer than those with low expression of TOX in patients received adjuvant therapies, especially in patients with chemotherapy (DFS: 72.85 vs. 64.53 months, P=0.00029; OS: 82.06 vs. 74.29 months, P=0.00033). Based on the Cox model regression analyses for DFS and OS, multivariate analysis indicated that TOX [DFS, hazard ratio (HR): 0.412, 95%CI: 0.248-0.684, P=0.001); OS, HR: 0.395, 95%CI: 0.237-0.660, P＜0.0001] was the potential prognostic factor. The established nomogram was used to predict survival and the calibration curve analysis had performed that the predicted line was well-matched with base line in postoperative 1-, 3-, and 5-year survival rate. Conclusions: The expression of TOX is a potential prognostic factor, and can be a promising biomarker for predicting survival and guiding treatment strategy in breast cancer patients.

show abstract

Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines

Cited by 24 publications

References 223 publications

Current status and future of cancer vaccines: A bibliographic study

Current status and future of cancer vaccines: A bibliographic study

Influence of Microbiota on Tumor Immunotherapy

Low expression of TOX predicts poor prognosis of patients with breast cancer in the real world: a retrospective study

Contact Info

Product

Resources

About